SOAT1 and COVID-19: In particular, IL-6 might be a promising biomarker for severity and therapeutic decision-making, as antagonizing the IL-6 directly or through the JAK-STAT pathway has demonstrated improved prognosis in hospitalised COVID-19 patients with hypoxia and systemic inflammation [19, 20].